LumiraDX And BIVDA Speak On Challenges Of Driving Adoption Of Valuable Diagnostics
Diagnostics such as c-reactive protein tests are more sensitive than ever before, but manufacturers are still struggling to place them in primary care and community settings where they can make huge differences.
You may also be interested in...
Is Osler Diagnostics The Next Theranos Or Can It Surprise Everyone?
Founded with a vision to change point-of-care diagnostics, Osler Diagnostics has raised nearly $200m to develop and commercialize a platform that promises to revolutionize diagnostics with just a drop of a patients’ blood.
Analyst Insight: Justifying A Price Target Following Poor SPAC Reception
In a discussion with Medtech Insight, analysts at Ladenburg Thalmann argued the case for their LumiraDX $14.75 price target.
AstraZeneca And Huma On Digital’s Value For Pharma
Digital tools have long been of interest to pharma for their potential to transform many aspects of drug development, leading to many collaborations between pharma and medtech firms. Here, two companies that have been working together to develop a series of software-based tools for monitoring patients – AstraZeneca and Huma – discuss the value of these partnerships and their potential challenges.